A5059834254- Prostate Cancer Treatment and Research
- Advanced Radiotherapy Techniques
- Prostate Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Breast Cancer Treatment Studies
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Cancer Treatment and Pharmacology
- Head and Neck Cancer Studies
- Brain Metastases and Treatment
- Endometrial and Cervical Cancer Treatments
- Management of metastatic bone disease
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Radiation Therapy and Dosimetry
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Renal cell carcinoma treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Bladder and Urothelial Cancer Treatments
- Medical Imaging and Analysis
- AI in cancer detection
- Advances in Oncology and Radiotherapy
- Cancer Genomics and Diagnostics
Azienda Ospedaliero-Universitaria Careggi
2013-2025
University of Florence
2016-2025
University of Bari Aldo Moro
2021
Mary Bird Perkins Cancer Center
2019
Berkeley College
2019
University of California, Berkeley
2019
Florence (Netherlands)
2011-2015
PURPOSE ARTO (ClinicalTrials.gov identifier: NCT03449719 ) is a multicenter, phase II randomized clinical trial testing the benefit of adding stereotactic body radiation therapy (SBRT) to abiraterone acetate and prednisone (AAP) in patients with oligometastatic castrate-resistant prostate cancer (CRPC). MATERIALS AND METHODS All were affected by CRPC as defined three or less nonvisceral metastatic lesions. Patients randomly assigned 1:1 receive either AAP alone (control arm) concomitant SBRT...
Highlights•Off-target ILDR synergizes with anti-PD-L1 to eradicate non-irradiated tumors•The abscopal effects of depend on dosimetry (≥1 and ≤3 Gy) volume•Gut composition governs the combined anti-PD-L1•ILDR Christensenellaceae influence emigration intestinal mregDC TdLNSummaryThe mechanisms governing local radiotherapy in cancer patients remain an open conundrum. Here, we show that off-target low-dose irradiation (ILDR) increases clinical benefits immune checkpoint inhibitors or...
Preoperative partial breast irradiation (PBI) has got the advantage of treating a well-defined target. We report results phase II ROCK trial (NCT03520894), enrolling early cancer (BC) patients treated with preoperative robotic radiosurgery (prRS), in terms acute and late toxicity, disease control, cosmesis.The study recruited between 2018 2021 at our Radiation Oncology Unit. Eligible were 50 + years old BC, hormonal receptors positive/human epidermal growth factor receptor 2 negative...
397 Background: ARTO (NCT03449719) was a multicenter randomized phase II trial exploring the benefit of concomitant Abiraterone acetate and stereotactic body radiotherapy (SBRT) administration in oligometastatic castrate resistant prostate cancer patients (omCRPC). Both biochemical response progression free survival (bPFS) were improved by addition SBRT experimental arm if compared to abiraterone alone. Here is presented secondary analysis focusing on prognostic impact BRCA alterations...
160 Background: Apalutamide+androgen deprivation therapy (ADT) showed to significantly improve overall survival in low and high volume metastatic hormone sensitive prostate cancer (mHSPC) if compared ADT alone. However, a randomized phase II trial (ARTO, NCT03449719) suggested that stereotactic body radiotherapy (SBRT) improved clinical outcomes when administered concomitantly with abiraterone acetate castration resistance (mCRPC). Nonetheless, evidence related use of SBRT addition androgen...
To investigate the effects of radical radiotherapy (RT) relevant interruptions (RRI), single (sRRI) or multiple (mRRI), on Biochemical Failure-Free Survival (BFFS), Metastases-Free (MFS) and Overall (OS) in prostate cancer (PCa) patients. We conducted a retrospective analysis involving 383 patients diagnosed with who received RT between March 2013 April 2021, doses ranging from 60 to 80 Gy (median dose 76.0 Gy), either alone combination androgen deprivation therapy. The study aimed evaluate...
Abstract BACKGROUND: The objective of this study was to evaluate prognostic factors local and distant recurrence in patients diagnosed with T1a T1b, lymph node‐negative breast carcinoma (BC) emphasis on human epidermal growth factor receptor 2 (HER2) status. METHODS: authors reviewed 704 women T1aT1bN0M0 BC who received treatment at the Radiation‐Oncology Center Florence University between November 2002 December 2008. Patients ductal situ or recurrent presentation adjuvant chemotherapy were...
Objective To assess the safety and effectiveness of stereotactic salvage radiotherapy (SSRT) in RT‐naïve patients affected by macroscopic prostate bed recurrence. Patients methods Consecutive treated for recurrence three different Italian institutes were reviewed. with SSRT, a total dose 30–40 Gy five fractions, mean pre‐SSRT PSA level was 2.3 ng/mL. Two thresholds defined biochemical recurrence‐free survival (BCRFS) reported, order to better express outcome: BCRFS1 (a increase >10%...
This retrospective work aims to evaluate the possible impact on intra- and inter-observer variability, contouring time, contour accuracy of introducing a pelvis computed tomography (CT) auto-segmentation tool in radiotherapy planning workflow.Tests were carried out five structures (bladder, rectum, pelvic lymph-nodes, femoral heads) six previously treated subjects, enrolling radiation oncologists (ROs) manually re-contour edit auto-contours generated with male CT atlas created commercial...
Objective This retrospective, multicenter study analyzes the efficacy and safety of stereotactic body radiotherapy in a large cohort patients with oligometastatic/persistent/recurrent cervical cancer. Methods A standardized data collection from several centers that treated by between March 2006 February 2021 was set up. Clinical parameters were collected. response rate defined as composite complete partial response, while clinical benefit included objective plus stable disease. Radiation...
PSICHE (NCT05022914) is a prospective trial to test [68Ga]Ga- PSMA-11 PET/CT imaging tailored strategy. All evaluable patients had biochemical relapse after surgery and underwent centralized [68Ga]Ga-PSMA-11 imaging. The treatment was performed according pre-defined criteria. Observation re-staging at further PSA progression were proposed with negative PSMA previous postoperative RT. Prostate bed SRT all staging or positive within prostate bed. Stereotactic body radiotherapy (SBRT) sites of...